Evolus saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an increase from 64 to 74.
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or better RS Rating as they begin their largest price moves. See if Evolus can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Evolus is trying to complete a cup with handle with a 17.12 buy point. See if it can break out in heavy trading.
The company showed 0% earnings growth in its most recent report. Sales increased 29%.
Evolus holds the No. 16 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR, Phibro Animal Health and Jazz Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
